Abcam, ab245831, Anti-MIP-1 alpha/CCL3 + CCL4/MIP-1 beta + CCL3L1 + CCL4L1 antibody [EPR19900-275] - BSA & Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MIP-1 alpha/CCL3 antibody. Carrier free. Suitable for ICC/IF, WB, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR19900-275,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab245831 is the carrier-free version of
ab206429
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MIP-1 alpha also known as CCL3 and MIP-1 beta known as CCL4 are key chemokines involved in the immune response. These proteins have a molecular mass of approximately 8 to 10 kDa. They are secreted by various cells including macrophages dendritic cells and lymphocytes. MIP-1 alpha and MIP-1 beta are part of the CC chemokine family and are secreted as monomers that bind to specific receptors on the surface of target cells attracting and activating them during inflammation and immune responses.
Biological function summary
These chemokines play significant roles in the recruitment and activation of leukocytes to sites of infection or injury. They are important elements in the immune defense system and help to orchestrate the movement and coordination of immune cells. MIP-1 alpha and MIP-1 beta function in synergy with other chemokines and cytokines enhancing the body's ability to respond to pathogens. While they do not form part of a larger complex their interaction with chemokine receptors like CCR1 CCR4 and CCR5 is critical for their function.
Pathways
MIP-1 alpha and MIP-1 beta participate in inflammatory and immune pathways. They are key mediators in the chemokine signaling pathway linked especially with the activation of the MAPK and NF-kB pathways. These chemokines work closely with related chemokines such as CCL5 (RANTES) and cytokines like TNF-alpha amplifying the body's response to immune challenges.
MIP-1 alpha and MIP-1 beta have connections to several pathological conditions particularly inflammatory diseases and HIV. Their levels often increase in diseases like rheumatoid arthritis reflecting their role in inflammatory processes. In the context of HIV infection these chemokines inhibit viral entry by blocking the CCR5 receptor which is important for some strains of the virus. This highlights their therapeutic potential in designing treatments targeting HIV alongside other inflammatory conditions.